Highest-materiality recent filing
Haemonetics acquires Vivasure Medical for up to €185M; upfront €100M plus €85M earn-out
Acquired all equity of Vivasure Medical, a Galway, Ireland-based developer of percutaneous vessel closure technology.
Haemonetics completes sale of whole blood assets to GVS for up to $67.8M
Total cash consideration up to $67.8M: $45.3M upfront (adjusted) plus up to $22.5M contingent.
Haemonetics sells whole blood assets to GVS for $44.6M cash plus up to $22.5M earnout
Total consideration up to $67.1M: $44.6M cash at close plus up to $22.5M contingent on sales growth and milestones.
Issued $700M (incl. $100M greenshoe) of 2.50% Convertible Senior Notes due June 1, 2029.
Haemonetics prices $600M 2.50% convertible notes due 2029; to repurchase $200M of 2026 notes
$600M 2.50% convertible senior notes due 2029 priced; initial conversion price ~$117.12/share (30% premium over $90.09 closing).
Haemonetics enters $1B credit agreement; $250M term loan, $750M revolver due 2029
New $250M senior unsecured term loan retires existing term loan under 2022 credit agreement.
Haemonetics to acquire Attune Medical for $160M upfront; device complements EP portfolio
Upfront cash $160M plus contingent consideration based on sales growth and milestones.
On April 27, 2026, Charles J. Dockendorff informed Haemonetics Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Shareholders (the “2026 Annual Meeting”).
On March 3, 2025, Haemonetics Corporation (the “Company”) announced the appointment of Frank W. Chan, Ph.D. as its Executive Vice President, Chief Operating Officer, effective April 7, 2025.
Josep Llorens, Executive Vice President, Global Manufacturing and Supply Chain, has notified Haemonetics Corporation (the “Company”) of his decision to retire from the Company effective July 11, 2025.
Anila Lingamneni, Executive Vice President, Chief Technology Officer, will leave Haemonetics Corporation (the “Company”) on November 1, 2024.
Max materiality 0.70 · Median 0.50 · Most common event earnings